Nutrition supplement company will be folded into the French food group's advanced medical nutrition
Orchid, an India-based company, creates this way its presence in the front-end US market.
Sandoz will have a licence to sell a generic version of the drug from September 2012.
The US-based clinical research company expands its position in Europe with equity position in German
OSI is expected to augment Astellas's current focus on urology and transplantation.
New strategy for healthcare providers will include a drug reference app for the iPhone.
Novella acquires the Ohio-based clinical research organisation which specialises in oncology drugs.
Move is part of an effort to keep costs down, according to a new report.
Danish group Leo Pharma suspends Greek sales following government austerity measures.
Agreement will initially run for three years, after which OMJ has option to extend the alliance.
CEO of Sanofi-aventis: "We are very pleased to collaborate with the Charité, one of Europe's top-cla
Amgen said that the European Commission (EC) has granted marketing authorization for Prolia (denosum
Alvine Pharmaceuticals, a privately held clinical stage biopharmaceutical company focused on develop
Valeant Pharmaceuticals International has acquired Lawrenceville, New Jersey-based Aton Pharma, a sp
Public offering of £1bn planned.
The company took over major rival Wyeth last October, for $67bn.
Technology solutions firm seeks merger in order to expand into Latin America.
The company has posted a net profit of $0.21m for the first quarter 2010.
China Medicine has announced a net income of $1.79m for the first quarter of 2010.
Atypical antipsychotics are used for treating schizophrenia, bipolar mania and acute mania and are s
The recommendation was based on a data review from a program which included 35 clinical studies on m
Two different dosing schedules of Pixantrone will be tested.
Settlement expected to resolve more than 700 lawsuits.
Revenues of $1.2m compared to $2m reported in the comparable year-ago quarter.
Abbott expected to gain rights to at least 24 Zydus products.
Company reports net sales of $542m.
The all share transaction is expected to close on or before June 15.
Company posts net income of $330.2m.
The companies expect to submit in early 2011.
Nasdaq-listed company Dendreon has received approval from the US Food and Drugs Agency (FDA) to comm